REPLIGEN CORP
Analysts updated ratings and price targets for several companies. Notable changes include Datadog (DDOG) upgraded to outperform with a raised target to $350, Intel (INTC) upgraded to neutral with a $85 target, and MGM Resorts (MGM) maintained as underweight with a reduced target to $29. Other companies affected include Boyd Gaming (BYD), Bxp (BXP), and Fair Isaac (FICO).
Repligen Corp. (RGEN) awarded its Chief Product Officer 700 restricted stock units and options for 675 shares. The RSUs vest over three years, while options vest annually until 2029 and expire in 2036. The options have a $174.86 exercise price. Douglass now holds 8,685 shares directly.
Repligen Corp. (NASDAQ:RGEN) CEO Olivier Loeillot sold 5,535 shares for $1.03m and acquired 4,202 shares via options. Shares are up 62% in six months, with a market cap of $9.9b. Q2 earnings beat estimates, with revenue at $204m. UBS maintains a Buy rating with a $225 target, while Canaccord Genuity keeps a Hold rating with a $145 target.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning RGEN (REPLIGEN CORP). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent RGEN coverage spans financial news, mergers & acquisitions and insider activity.
In the last 30 days, RGEN insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($4.5M). The most active reporter was Loeillot Olivier, Chief Executive Officer, with 5 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive impact from higher target.
The insider grant adds dilution but is modest in size relative to market cap.
The insider sale may create modest selling pressure, but the simultaneous option exercise purchase offsets some of that impact.
The insider sale may signal confidence concerns, likely exerting downward pressure on the stock.
No new information; earnings already known.
AlphAI scores every news story that mentions RGEN with an AI model for sentiment and relevance, and aggregates insider trades from REPLIGEN CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts updated ratings and price targets for several companies. Notable changes include Datadog (DDOG) upgraded to outperform with a raised target to $350, Intel (INTC) upgraded to neutral with a $85 target, and MGM Resorts (MGM) maintained as underweight with a reduced target to $29. Other companies affected include Boyd Gaming (BYD), Bxp (BXP), and Fair Isaac (FICO).
3 min readRepligen Corp. (RGEN) awarded its Chief Product Officer 700 restricted stock units and options for 675 shares. The RSUs vest over three years, while options vest annually until 2029 and expire in 2036. The options have a $174.86 exercise price. Douglass now holds 8,685 shares directly.
1 min readRepligen Corp. (NASDAQ:RGEN) CEO Olivier Loeillot sold 5,535 shares for $1.03m and acquired 4,202 shares via options. Shares are up 62% in six months, with a market cap of $9.9b. Q2 earnings beat estimates, with revenue at $204m. UBS maintains a Buy rating with a $225 target, while Canaccord Genuity keeps a Hold rating with a $145 target.
1 min readLoeillot Olivier (Chief Executive Officer) sold 5,535 shares of REPLIGEN CORP (RGEN) at an average of $187.29 ($178.75–$190.00, $1.04M total) across 2 trades on 2026-10-05 under a Rule 10b5-1 trading plan.
1 min readAzenta reported Q2 revenues of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B in revenues, up 8.7% YoY, exceeding expectations. Charles River Laboratories reported $1.00B in revenues, down 2.7% YoY, but beating estimates. Repligen reported $204.1M in revenues, up 11.9% YoY, also beating estimates. All stocks have seen significant gains since reporting.
2 min readBIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. At the effective time of the First Merger (the “First Merger Effective Time”), ea
2 min readRepligen Corporation (NASDAQ: RGEN) completed its acquisition of BioLife Solutions (NASDAQ: BLFS) for $11.25 per share in cash and 0.1442 shares of Repligen stock. The deal expands Repligen's presence in the cell therapy market, adding high-margin consumables and recurring revenue. BioLife's products support 18 approved therapies and most U.S. cell-based therapy trials. Repligen will discuss the transaction's financial impact on its Q3 2026 earnings call.
1 min readS&P Dow Jones Indices announced Freshworks (FRSH) will replace BioLife Solutions (BLFS) in the S&P SmallCap 600 on October 8, 2026. Repligen (RGN) is acquiring BioLife for $1.5B, with BioLife shareholders receiving $11.25 per share in cash and 0.1442 shares of Repligen stock. Freshworks reported Q2 2026 revenue of $237.4M, up 16% YoY, and its first GAAP profitability in 2026.
3 min readRepligen Corp (RGEN) executive Olivier Loeillot filed a Form 144 notice to sell 4,202 shares worth $798,380. The sale is expected on October 5, 2026. The notice also lists four prior sales by Loeillot in the last three months.
1 min readKodiak Sciences (KOD) surged 177% to a 52-week high after positive Phase 3 trial results for its retinal disease drug. Grail (GRAL) rose 4% following FDA panel support for its cancer detection test. Iovance (IOVA) gained 7% after raising revenue guidance. Repligen (RGEN) climbed 2% with 12% revenue growth reported.
2 min read
